HYPMY Stock - Hypera S.A.
Unlock GoAI Insights for HYPMY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $7.44B | $7.91B | $7.55B | $5.94B | $4.09B |
| Gross Profit | $4.38B | $5.00B | $4.76B | $3.80B | $2.63B |
| Gross Margin | 58.9% | 63.1% | 63.1% | 64.0% | 64.3% |
| Operating Income | $1.80B | $2.29B | $2.64B | $2.04B | $1.40B |
| Net Income | $1.34B | $1.65B | $1.70B | $1.33B | $1.30B |
| Net Margin | 18.0% | 20.8% | 22.5% | 22.4% | 31.7% |
| EPS | $2.12 | $2.58 | $2.68 | $2.10 | $2.05 |
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 18th 2022 | Goldman | Upgrade | Buy | - |
Earnings History & Surprises
HYPMYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 21, 2026 | — | — | — | — |
Q1 2026 | Mar 18, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | — | $0.13 | — | — |
Q3 2025 | Aug 6, 2025 | — | $0.12 | — | — |
Q2 2025 | Apr 23, 2025 | — | $-0.04 | — | — |
Q4 2024 | Dec 31, 2024 | — | $0.02 | — | — |
Q4 2024 | Nov 13, 2024 | — | $0.11 | — | — |
Q3 2024 | Jul 25, 2024 | — | $0.15 | — | — |
Q2 2024 | Apr 26, 2024 | — | $0.12 | — | — |
Q4 2023 | Dec 30, 2023 | — | $0.10 | — | — |
Q4 2023 | Oct 26, 2023 | — | $0.16 | — | — |
Q2 2023 | Jun 30, 2023 | — | $0.16 | — | — |
Q2 2023 | Apr 27, 2023 | — | $0.10 | — | — |
Q4 2022 | Dec 31, 2022 | — | $0.12 | — | — |
Q3 2022 | Sep 30, 2022 | — | $0.14 | — | — |
Q3 2022 | Jul 29, 2022 | — | $0.15 | — | — |
Q2 2022 | Apr 28, 2022 | — | $0.10 | — | — |
Q1 2022 | Feb 24, 2022 | — | $0.10 | — | — |
Q4 2021 | Oct 22, 2021 | — | $0.14 | — | — |
Q3 2021 | Jul 23, 2021 | — | $0.14 | — | — |
Latest News
Frequently Asked Questions about HYPMY
What is HYPMY's current stock price?
What is the analyst price target for HYPMY?
What sector is Hypera S.A. in?
What is HYPMY's market cap?
Does HYPMY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to HYPMY for comparison